NFE2L2 and cancer: Epigenetic silencing of KEAP1 by hypermethylation of its promoter causes an increase in Nrf2 expression levels in lung (114, 177), prostate (194), colorectal cancers (45) and gliomas (113), conferring a growth advantage to the cancer cells.